Trial reportThe Journal of allergy and clinical immunology2021
Epicutaneous immunotherapy for treatment of peanut allergy: Follow-up from the Consortium for Food Allergy Research.
Trial report in The Journal of allergy and clinical immunology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 3 syntheses or guidelines pooled it, 54 citations in OpenAlex.
- Precision Medicine in Plant Food Allergy: a Systematic Review of Biomarkers Under a Clinical Approach.Clinical reviews in allergy & immunology · 2026Pooled it
- Epicutaneous immunotherapy for food allergy: a systematic review and meta-analysis.Systematic reviews · 2025Pooled it
- Racial and Ethnic Representation in Food Allergen Immunotherapy Trial Participants: A Systematic Review.JAMA network open · 2024Pooled it
- Allergen-specific T cells and clinical features of food allergy: Lessons from CoFAR immunotherapy cohorts.The Journal of allergy and clinical immunology · 2022Trial
- Decoding Early Clues: Immune Mechanisms, Prevention, Diagnosis, and Treatment of IgE-Mediated Peanut and Tree Nut Allergy in Children.Biomedicines · 2025Review
- Epicutaneous immunotherapy for food allergy: A systematic review and meta-analysis.Clinical and translational allergy · 2025Review
- Considerations for biologics as front-line treatment in allergic diseases.Frontiers in immunology · 2025Review
- The Future of Food Allergy Management: Advancements in Therapies.Current allergy and asthma reports · 2024Review
- Practical issues of oral immunotherapy for egg or milk allergy.Clinical and experimental pediatrics · 2024Article
- Food Allergen Immunotherapy in the Treatment of Patients with IgE-Mediated Food Allergy.Medicina (Kaunas, Lithuania) · 2024Review
- Alanine Scanning of the Unstructured Region of Ara h 2 and of a Related Mimotope Reveals Critical Amino Acids for IgE Binding.Molecular nutrition & food research · 2023Article
- Factor IX administration in the skin primes inhibitor formation and sensitizes hemophilia B mice to systemic factor IX administration.Research and practice in thrombosis and haemostasis · 2023Article
- Review
- Update on clinical research for food allergy treatment.Frontiers in allergy · 2023Review
- Immune signatures predicting the clinical outcome of peanut oral immunotherapy: where we stand.Frontiers in allergy · 2023Review
- Preclinical evaluation of alternatives to oral immunotherapy for food allergies.Frontiers in allergy · 2023Review
- Transitioning from epicutaneous to oral peanut immunotherapy.Frontiers in allergy · 2023Article
- Immunology of allergen immunotherapy.Immunotherapy advances · 2022Review
- Oral Immunotherapy for Children with Cow's Milk Allergy.Pathogens (Basel, Switzerland) · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 8 institutions in 1 country.
Funding
Abstract
backgroundConsortium for Food Allergy Research investigators previously reported 52-week outcomes from a randomized controlled trial of peanut epicutaneous immunotherapy, observing modest and statistically significant induction of desensitization, highest in children ages 4 to 11 years.
objectiveWe sought to evaluate changes in efficacy, safety, and mechanistic parameters following extended open-label peanut epicutaneous immunotherapy.
methodsPeanut-allergic participants (4-25 years) received 52 weeks of placebo (PLB), Viaskin Peanut 100 μg (VP100) or 250 μg (VP250), and then crossed over to VP250 for PLB (PLB-VP250) and VP100 (VP100-VP250) participants and continued treatment for VP250 participants (total = 130 weeks of active epicutaneous immunotherapy). Efficacy was assessed by double-blind, placebo-controlled food challenge (5044 mg peanut protein), and adherence, safety, and mechanistic parameters were evaluated.
resultsAt week 130, desensitization success was achieved in 1 of 20 (5%) PLB-VP250, 5 of 24 (20.8%) VP100-VP250, and 9 of 25 (36%) VP250 participants, with median successfully consumed dose change from baseline of 11.5 mg, 141.5 mg, and 400 mg, respectively. Median age (years) for week 130 desensitization success was 6.2 years (interquartile range, 5.2-9.1) versus 9.4 years (interquartile range, 7.6-12.8) for failures (P < .001). Adherence was 96%. Adverse reactions were predominantly local patch-site reactions. Significant increases in peanut- and Ara h2-specific IgG
conclusionsExtended treatment with VP250 was well tolerated, and desensitization observed at week 52 persisted between weeks 52 and 130. Treatment success was observed predominantly in younger participants, with younger age at initiation of active therapy an important predictor of success.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.